Sunday, October 01, 2017 4:49:00 AM
Basically, they have data showing oral eravacycline achieved therapeutic drug ranges in urine when taken fasting. Thus, the oral formulation of the drug does in fact work just fine. The whole entire fail of the trial back in 2015 leading to a loss of 80% of TTPH share value was all due to people eating before taking the pill......
https://idsa.confex.com/idsa/2017/webprogram/Paper66183.html
Conclusion:
These results support the conclusion that oral dosing in the previous phase 3 study resulted in low ERV exposures and urine concentrations. The exposures and urine concentrations observed with IV ERV are well within the expected therapeutic range and support the efficacy of IV ERV in the treatment of cUTI. Day 7 results in the fasted period indicate that an IV to oral transition dose regimen for ERV is achievable and work is ongoing to optimize dose and meal schedule.
Patrick Horn, MD, PhD, Tetraphase Pharmaceuticals, Watertown, MA, Susan Redican, MS, Clinical Operations, Tetraphase Pharmaceuticals, Watertown, MA and Larry Tsai, MD, Clinical, Tetraphase Pharmaceuticals, Watertown, MA
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM